Afficher la notice abrégée

Complementary use of mass spectrometry and cryo-electron microscopy to assess the maturity of live attenuated dengue vaccine viruses

dc.rights.licenseopenen_US
dc.contributor.authorTRAUCHESSEC, Mathieu
dc.contributor.authorLAMBERT, Olivier
hal.structure.identifierInstitut Européen de Chimie et Biologie [IECB]
hal.structure.identifierChimie et Biologie des Membranes et des Nanoobjets [CBMN]
hal.structure.identifierAcides Nucléiques : Régulations Naturelle et Artificielle [ARNA]
dc.contributor.authorBONNAFOUS, Pierre
dc.contributor.authorBERARD, Yves
dc.contributor.authorBARRIERE, Fabienne
dc.contributor.authorHUILLET, Celine
dc.contributor.authorMARCO, Sergio
dc.contributor.authorSIROHI, Devika
dc.contributor.authorHEDRICK, Victoria
dc.contributor.authorKUHN, Richard
dc.contributor.authorGUY, Bruno
dc.contributor.authorRONZON, Frederic
dc.contributor.authorMANIN, Catherine
dc.date.accessioned2020-04-22T12:36:59Z
dc.date.available2020-04-22T12:36:59Z
dc.date.issued2019
dc.identifier.issn0264-410Xen_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/4355
dc.description.abstractEnDengue virus (DENV) infection is a global health threat with the potential to affect at least 3.6 billion people living in areas of risk. No specific curative treatments against dengue disease are available and vaccines are currently the only way to prevent the disease. The tetravalent dengue vaccine developed by Sanofi Pasteur has demonstrated significant efficacy in phase III studies and is now licensed in several countries for the prevention of disease in dengue-seropositives over 9 years of age. The vaccine is composed of four recombinant, live, attenuated vaccines (CYD 1-4) based on a yellow fever vaccine 17D (YFV 17D) backbone, each expressing the pre-membrane (prM) and envelope (E) genes of one of the four DENV serotypes. Virus maturity could impact the biological activity of the vaccine viruses. To address this question, the maturity of the four vaccine viruses used in phase III clinical studies was assessed by two complementary techniques: mass spectrometry (MS) and cryo-electron microscopy (cryoEM). MS assessed viral maturity at the molecular level by quantifying specifically the prM, and M proteins. CryoEM provided information at the particle level, allowing visualizing the different phenotypes of viral particles: spiky (immature), smooth/bumpy (mature), and mixed (partially mature). Results of the two assays used in this study show that all four CYD dengue vaccine viruses present in lots used in phase III efficacy trials, display in the majority a mature phenotype. (C) 2019 Elsevier Ltd. All rights reserved.
dc.language.isoENen_US
dc.subject.enDengue vaccine
dc.subject.enVirus maturity
dc.subject.enMass spectrometry
dc.subject.enCryo-electron microscopy
dc.title.enComplementary use of mass spectrometry and cryo-electron microscopy to assess the maturity of live attenuated dengue vaccine viruses
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.vaccine.2019.05.012
dc.subject.halChimie/Matériauxen_US
bordeaux.journalVaccineen_US
bordeaux.page3580-3587en_US
bordeaux.volume37en_US
bordeaux.hal.laboratoriesInstitut de Chimie & de Biologie des Membranes & des Nano-objets (CBMN) - UMR 5248en_US
bordeaux.issue27en_US
bordeaux.institutionBordeaux INPen_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03182120
hal.version1
hal.date.transferred2021-03-26T09:39:12Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Vaccine&rft.date=2019&rft.volume=37&rft.issue=27&rft.spage=3580-3587&rft.epage=3580-3587&rft.eissn=0264-410X&rft.issn=0264-410X&rft.au=TRAUCHESSEC,%20Mathieu&LAMBERT,%20Olivier&BONNAFOUS,%20Pierre&BERARD,%20Yves&BARRIERE,%20Fabienne&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée